SCHEMBL7247677

SCHEMBL7247677

CN(C)CCOc1cc(NS(=O)(=O)c2c(Cl)ccc(Cl)c2Cl)ccc1Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 4/20 0.49
FABP4 P15090 1/20 0.43
LMNA P02545 5/20 0.42
ALDH1A1 P00352 4/20 0.42
MAPT P10636 3/20 0.42
XBP1 P17861 2/20 0.42
HTT P42858 2/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
GAA P10253 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
KDR P35968 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HDAC1 Q13547 3/20 0.36
HDAC2 Q92769 3/20 0.36
HDAC8 Q9BY41 3/20 0.36
HDAC6 Q9UBN7 3/20 0.36
MAOA P21397 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542141 0.88 UTS2R (0.49) UTS2RFABP4LMNAALDH1A1MAPT
SCHEMBL6543128 0.86 UTS2R (0.47) UTS2RFABP4LMNAALDH1A1MAPT
SCHEMBL6542775 0.85 UTS2R (0.52) UTS2RFABP4LMNAALDH1A1MAPT
SCHEMBL6542898 0.84 UTS2R (0.51) UTS2RFABP4LMNAALDH1A1MAPT
Sb611812 SCHEMBL6542569 0.83 UTS2R (0.53) UTS2RFABP4LMNAALDH1A1MAPT
SCHEMBL6542669 0.81 UTS2R (0.53) UTS2RFABP4LMNAALDH1A1MAPT
SCHEMBL6542559 0.81 PPARG (0.48) UTS2RLMNAALDH1A1MAPTHTT
SCHEMBL6542576 0.81 UTS2R (0.60) UTS2RLMNAALDH1A1MAPTHTT
SCHEMBL6541903 0.81 LMNA (0.51) UTS2RFABP4LMNAALDH1A1MAPT
SCHEMBL6541457 0.81 SMN1; SMN2 (0.59) UTS2RFABP4LMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR UTS2R 1/4885FABP4 2008/4885LMNA 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.